RecruitingPhase 3NCT07255209

A Study of IBI362 in Chinese Adolescents With Obesity or Overweight

A Randomized, Double-blind, Placebo-controlled Phase 3 Clinical Trial to Assess the Efficacy and Safety of IBI362 in Chinese Adolescents With Obesity or Overweight（GLORY-YOUNG）

Sponsor

Innovent Biologics (Suzhou) Co. Ltd.

Enrollment

180 participants

Start Date

Dec 29, 2025

Study Type

INTERVENTIONAL

Conditions

Adolescents With Obesity or Overweight With Weight-Related Comorbidities

Summary

The study is designed to assess the efficacy and safety of multiple doses of IBI362 in Chinese adolescent subjects with obesity or overweight. It plans to enroll 180 adolescents (aged ≥12 and \<18 years) who have failed to achieve a 5 kg weight reduction after at least 12 weeks of dietary and exercise intervention.

Eligibility

Min Age: 12 YearsMax Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called IBI362 and a drug called Placebo for people with adolescents with obesity or overweight with weight-related comorbidities. The study is currently recruiting participants at 1 location. People eligible for this study include aged 12 Years to 18 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGPlacebo

Placebo SA.QW

DRUGIBI362

IBI362 SA.QW

Locations(1)

The Children's Hospital, Zhejiang University School of Medicine

Hangzhou, Zhejiang, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07255209